Invention Application
- Patent Title: ANTI-CD19 THERAPY IN PATIENTS HAVING A LIMITED NUMBER OF NK CELLS
-
Application No.: US17605285Application Date: 2020-05-04
-
Publication No.: US20220242952A1Publication Date: 2022-08-04
- Inventor: Christian KUFFER , Guenter FINGERLE-ROWSON , Mark WINDERLICH , Jan ENDELL
- Applicant: MORPHOSYS AG
- Applicant Address: DE Planegg
- Assignee: MORPHOSYS AG
- Current Assignee: MORPHOSYS AG
- Current Assignee Address: DE Planegg
- Priority: EP19172495.4 20190503
- International Application: PCT/EP2020/062289 WO 20200504
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61P35/00
Abstract:
The present disclosure provides characteristics and biomarkers in patients that benefit from treatment with anti-CD19 antibodies (MOR00208, XmAb5574). Furthermore, the present application relates to anti-CD19 antibodies for the treatment of leukemia or lymphoma in patients having a peripheral NK cell count at baseline of less or equal to 100 NK cells/μl
Information query
